로딩 중…
지수 로딩 중…
HUTCHMED (China) Limited
HCM· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
HK
$11.55+3.77%
2026-08-03
Financials
Valuation Metrics
HUTCHMED (China) Limited's Market Cap is $1.99B. At end of 2025 it was $2.33B. Ranked #2062 of 3,112 in US market (top 66%), #792 of 1,445 on NASDAQ (top 55%), #136 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.99B | US#2,062/3,112 Sec#136/269 |
| Revenue | $549M | US#2,304/3,112 Sec#77/269 |
| Net Income | $457M | US#859/3,112 Sec#34/269 |
| Total Assets | $1.75B | US#2,143/3,112 Sec#56/269 |
| Net Assets | $1.24B | US#1,625/3,112 Sec#54/269 |
| Value | ||
| P/E | 4.35x | US#28/3,112 Sec#4/269 |
| P/B | 1.60x | US#913/3,112 Sec#42/269 |
| P/S | 3.62x | US#1,981/3,112 Sec#58/269 |
| FCF Yield | -3.97% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | 36.91% | US#193/3,112 Sec#22/269 |
| ROA | 26.06% | US#42/3,112 Sec#9/269 |
| Op. Margin | -7.14% | US#2,596/3,112 Sec#94/269 |
| Revenue Growth | -16.54% | US#2,742/3,112 Sec#150/269 |
| Earnings Growth | -83.61% | US#2,006/3,112 Sec#60/269 |
| Financial Health | ||
| Debt Ratio | 40.54% | US#464/3,112 Sec#128/269 |
| Total Debt | $98M | US#2,395/3,112 Sec#118/269 |
| FCF | $-79M | US#2,542/3,112 Sec#135/269 |
| Cash | $71M | US#2,405/3,112 Sec#203/269 |
| Current Ratio | 4.96x | US#473/3,112 Sec#144/269 |
| Performance | ||
| 1Y Return | -33.12% | US#2,795/3,112 Sec#229/269 |
| 1M Return | 0.96% | US#1,504/3,112 Sec#63/269 |
| From 52W High | -36.89% | US#2,429/3,112 Sec#186/269 |
| 1Y MDD | -48.00% | US#2,324/3,112 Sec#178/269 |
| Trading | ||
| Volume | 81,304 shares | US#2,993/3,112 Sec#266/269 |
| Trading Value | $931743.00 | US#3,033/3,112 Sec#259/269 |
| Per Share | ||
| EPS | $2.69 | US#1,058/3,112 Sec#34/269 |
| BPS | $7.21 | US#2,017/3,112 Sec#100/269 |